<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00924391</url>
  </required_header>
  <id_info>
    <org_study_id>WWB2007:110</org_study_id>
    <nct_id>NCT00924391</nct_id>
  </id_info>
  <brief_title>Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans</brief_title>
  <official_title>Efficacy of Sterol Enhanced Soy Beverage on Cholesterol Metabolism, Inflammation and Oxidative Status in Humans Study 1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WhiteWave Foods, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is becoming increasingly clear that North Americans prefer dietary approaches to enhance&#xD;
      health in favour of pharmaceutical approaches. Although the consumption of various&#xD;
      phytosterol (PS)-enriched foods have been shown to be effective in lowering plasma&#xD;
      cholesterol in a variety of food matrices, the lipid-lowering potential of PS-enriched&#xD;
      soymilk has not been investigated. Therefore, the objective of this investigation was to&#xD;
      examine the lipid-lowering efficacy of a PS-enriched soymilk beverage in comparison to a 1%&#xD;
      dairy milk control. Twenty-three hypercholesterolemic subjects (Total-cholesterol and&#xD;
      LDL-cholesterol â‰¥ 5.0 and 3.5 mmol/L, respectively) consumed 3 tetrapacs per day of a&#xD;
      phytosterol-enriched soy beverage providing 1.95g PS/d or a 1% dairy milk control. The study&#xD;
      was conducted as a 28 d controlled dietary intervention according to a completely randomized,&#xD;
      two-period cross-over design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cholesterol</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Coronary Heart Disease</condition>
  <arm_group>
    <arm_group_label>dairy milk</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control phase with 1% milk.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>phytosterol enhanced soy based beverage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment phase where control-phase diets are provided with phytosterol enhanced soy based beverage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>phytosterol enhanced soy based beverage</intervention_name>
    <arm_group_label>phytosterol enhanced soy based beverage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>1% milk</intervention_name>
    <arm_group_label>dairy milk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males and females, aged 19-60 yr, will be screened for determination of&#xD;
             fasting circulating LDL-cholesterol and TG levels.&#xD;
&#xD;
          2. Subjects accepted into the study will have plasma LDL-C 130-200 mg/dl, TG levels below&#xD;
             250 mg/dl.&#xD;
&#xD;
          3. The inclusion for body mass index (BMI) range will be 22 to 32 kg/m2.&#xD;
&#xD;
          4. Subjects must also demonstrate an ability to understand dietary procedures and&#xD;
             exercise procedures and be judged as compliant and motivated by the investigators.&#xD;
&#xD;
          5. Subjects will be permitted to take stable doses of thyroid hormone and&#xD;
             anti-hypertensive agents, as long as these are continued equivalently throughout the&#xD;
             duration of study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of recent (i.e. less than 3 months) or chronic use of oral hypolipidemic&#xD;
             therapy, including fish oils, or probucol within the last 6 months.&#xD;
&#xD;
          2. History of chronic use of alcohol (&gt; 2 drinks/day), systemic antibodies,&#xD;
             corticosteroids, androgens, or phenytoin.&#xD;
&#xD;
          3. Myocardial infarction, coronary artery bypass, or other major surgical procedures&#xD;
             within the last six months.&#xD;
&#xD;
          4. Recent onset of angina, congestive heart failure, inflammatory bowel disease,&#xD;
             pancreatitis, diabetes, or significant current (ie. onset within past three months)&#xD;
             gastrointestinal, renal, pulmonary, hepatic or biliary disease, or cancer (evidence of&#xD;
             active lesions, chemotherapy or surgery in the past year).&#xD;
&#xD;
          5. Exercise greater than 15 miles/wk or 4,000 kcal/wk.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter JH Jones, B.ScM.ScPh.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Richardson Centre for Functional Foods and Nutraceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods and Nutraceuticals</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 16, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>June 17, 2009</last_update_submitted>
  <last_update_submitted_qc>June 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Peter JH Jones</name_title>
    <organization>Richardson Centre for Functional Foods and Nutraceuticals</organization>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>plant sterols</keyword>
  <keyword>cholesterol absorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

